Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis

Clinical Cardiology

Volumn 32, Issue 4, 2009, Pages 187-192

  Duygu, Hamza ^a,c   Nalbantgil, Sanem ^a   Zoghi, Mehdi ^a   Ozerkan, Filiz ^a   Yildiz, Ahmet ^a   Akilli, Azem ^b   Akin, Mustafa ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Gazi Hospital   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG INFUSION; FEMALE; HEART CYCLE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTEGRATED BACKSCATTER ANALYSIS; MALE; SYMPTOMATOLOGY;

CARDIOTONIC AGENTS; DOBUTAMINE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDRAZONES; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PYRIDAZINES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 64949136321     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20313     Document Type: Article

References (32)

1. Bayram M, De Luca L, Massie BM, Gheorghiade M. Dobutamine, milrinone and dopamine in acute heart failure syndromes: a reassessment. Am J Cardiol. 2005;96:47G-58G.
2. Caldicott LD, Hawley K, Heppel R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial. Eur Heart J. 1993;14:696-700.
3. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol. 1996;19:21-30.
4. Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol. 1977;39:588-594.
5. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4: 515-529.
6. Hasenfuss G, Pieske B, Castell M, etal. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98: 2141-2147.
7. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-2227.
8. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol. 2005; 96:68G-73G
9. Soei LK, Sassen LM, Fan DS, et al. Myofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation. 1994;90:959-969.
10. Pieske B. Levosimendan in regional myocardial ischemia. Cardiovasc Drugs Ther. 2002;16:379-381.
11. Duygu H, Ozerkan F, Zoghi M, et al. Objective ischemic evidence in patients with myocardial bridging: ultrasonic tissue characterization with dobutamine stress integrated backscatter. JAm Soc Echocardiogr. 2007;20(6):717-723.
12. Lin LC, Yen RF, Hwang JJ, et al. Ultrasonic tissue characterization evaluates myocardial viability and ischemia in patients with coronary artery disease. Ultrasound Med Biol. 2000;26:759-769.
13. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-367.
14. Yock PG, Dopp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984;70:657-662.
15. Giannuzzi P, Imparato A, Temporelli PL, etal. Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in post-infarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 1994; 23:1630-1637.
16. Barzilai B, Vered Z, Mohr GA, etal. Myocardial ultrasonic backscatter for characterization of ischemia and reperfusion: Relationship to wall motion. Ultrasound Med Biol. 1990;16: 391-398.
17. Takiuchi S, Ito H, Iwakura K, et al. Ultrasonic tissue characterization predicts myocardial viability in early stage of reperfused acute myocardial infarction. Circulation. 1998;97:356-362.
18. Castaldo M, Funaro S, Veneroso G, Agati L Detection of residual tissue viability within the infarct zone in patients with acute myocardial infarction: Ultrasonic integrated backscatter analysis versus dobutamine stress echocardiography. J Am Soc Echocardiogr. 2000;13:358-367.
19. Picano E, Faletra F, Marini C, etal. Increased echodensity of transiently asynergic myocardium in humans: a novel echocardiographic sign of myocardial ischemia. J Am Coll Cardiol. 1993; 21:199-207.
20. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-base approach. Am Heart J. 2001;142:393-401.
21. Opie LH, Nathan D, Lubbe WF. Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am J Cardiol. 1979;43: 131-148.
22. Luotalahti M, Lammintausta O, Ukkonen H. Levosimendan, a calcium sensitizer and potassium channel opener, is safe and improves left ventricular function in acute myocardial infarction. Circulation. 1998;98(Suppl. I):105-106.
23. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-2182.
24. Moiseyev VS, Poder P, Adrejevs N, etal. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J. 2002;23: 1422-1432.
25. Follath F, Cleland JG, Just H, etal. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised doubleblind trial. Lancet. 2002;360:196-202.
26. Poder P, Eha J, Antila S, et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther. 2003;17:451-458.
27. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333: 249-259.
28. De Luca L, Proietti P, Celotto A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150:563-568.
29. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K channel in rat ventricular cells. J Pharmacol Exp Ther. 1997;283: 375-383.
30. Beanlands RS, Armstrong WF, Hicks RJ, etal. The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. JNucl Cardiol. 1994;1:3-16.
31. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1998;288:316-325.
32. Duygu H, Ozerkan F, Nalbantgil S, et al. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure. IntJ Cardiol. 2008; 123(2) :201-203.